CRL
Charles River Laboratories
285.10$
+2.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 32.2% | 27.0% | 24.2% | 28.2% | 23.3% | 21.8% | 21.9% | 18.1% | 18.9% | 19.6% | 18.6% | 20.3% | |
| 8.5% | 5.7% | 4.3% | 5.6% | 5.1% | 5.1% | 4.2% | 3.5% | 3.1% | 3.4% | 2.6% | 3.0% | |
| 8.5% | 5.7% | 4.3% | 5.6% | 5.1% | 5.1% | 4.2% | 3.5% | 3.1% | 3.4% | 2.6% | 3.0% | |
| 13.7% | 13.1% | 13.4% | 14.7% | 12.2% | 11.0% | 11.3% | 9.3% | 9.9% | 9.5% | 9.6% | 9.9% | |
| 4.7% | 4.5% | 3.5% | 3.9% | 3.3% | 3.4% | 3.4% | 2.8% | 3.4% | 4.6% | 3.7% | 4.2% | |
| 35.9% | 32.8% | 27.9% | 26.7% | 24.2% | 22.2% | 20.5% | 22.6% | 24.4% | 24.8% | 26.8% | 28.3% | |
| 17.0% | 21.2% | 29.0% | 27.5% | 32.3% | 32.8% | 32.9% | 38.6% | 37.5% | 37.8% | 37.8% | 38.7% | |
| 9.5% | 13.6% | 14.5% | 12.6% | 15.8% | 14.7% | 14.3% | 15.1% | 12.6% | 10.5% | 9.6% | 4.8% | |
| 62.6% | 63.0% | 68.5% | 63.7% | 65.3% | 64.5% | 61.0% | 63.1% | 60.2% | 55.4% | 53.4% | 55.0% | |
| 15.7% | 15.1% | 15.8% | 15.8% | 14.5% | 15.1% | 15.3% | 14.7% | 14.4% | 12.9% | 13.2% | 15.7% | |
| 1.7% | 0.8% | 1.0% | 1.1% | 0.9% | 1.3% | 1.4% | 0.5% | 0.7% | 5.4% | 1.5% | 0.9% | |
| 1.8% | 1.8% | 2.5% | 2.7% | 1.7% | 2.4% | 2.2% | 2.8% | 2.7% | 2.1% | 1.9% | 2.1% | |
| 39.6% | 40.9% | 44.5% | 38.0% | 42.4% | 38.8% | 34.7% | 37.6% | 35.6% | 32.3% | 29.8% | 29.6% | |
| 35.7% | 35.4% | 30.9% | 35.7% | 34.2% | 34.8% | 38.5% | 36.1% | 39.1% | 43.9% | 46.0% | 44.4% | |
| -7.4% | 0.5% | 6.1% | 9.9% | 1.1% | 6.0% | 11.4% | 14.0% | 18.8% | 23.0% | 24.1% | 19.5% | |
| 2.5% | 2.3% | 1.8% | 1.7% | 1.3% | 1.1% | 0.9% | 0.7% | 0.7% | 0.6% | 0.7% | 0.7% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.